The estimated Net Worth of Advisors Llc Orbi Med Capit... is at least $367 Million dollars as of 20 September 2021. Advisors Capit owns over 1,109,644 units of SI-BONE Inc stock worth over $104,710,302 and over the last 7 years Advisors sold SIBN stock worth over $261,907,249.
Advisors has made over 27 trades of the SI-BONE Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Advisors sold 10,280,947 units of SIBN stock worth $2,158,999 on 22 November 2022.
The largest trade Advisors's ever made was selling 10,280,947 units of SI-BONE Inc stock on 22 November 2022 worth over $2,158,999. On average, Advisors trades about 734,933 units every 59 days since 2018. As of 20 September 2021 Advisors still owns at least 6,943,654 units of SI-BONE Inc stock.
You can see the complete history of Advisors Capit stock trades at the bottom of the page.
Advisors's mailing address filed with the SEC is 601 LEXINGTON AVENUE601 LEXINGTON AVENUE, 54TH FLOOR54TH FLOOR, NEW YORKNEW YORK, NYNY, 1002210022.
Over the last 6 years, insiders at SI-BONE Inc have traded over $114,943,926 worth of SI-BONE Inc stock and bought 1,250,000 units worth $18,750,000 . The most active insiders traders include David P Bonita, Advisors Llc Orbi Med Capit..., and John Gordon Freund. On average, SI-BONE Inc executives and independent directors trade stock every 8 days with the average trade being worth of $401,535. The most recent stock trade was executed by Anshul Maheshwari on 3 September 2024, trading 1,414 units of SIBN stock currently worth $23,119.
si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al
SI-BONE Inc executives and other stock owners filed with the SEC include: